Regorafenib Versus Nivolumab After Sorafenib Failure: Real‐World Data in Patients With Hepatocellular Carcinoma

MLA

So Jung Lee, et al. “Regorafenib Versus Nivolumab After Sorafenib Failure: Real‐World Data in Patients With Hepatocellular Carcinoma.” Hepatology Communications, vol. 4, June 2020, pp. 1073–86. EBSCOhost, https://doi.org/10.1002/hep4.1523.

APA

So Jung Lee, Ju Hyun Shim, Young-Hwa Chung, Young-Sang Lee, Won Mook Choi, Kang Mo Kim, Danbi Lee, Han Chu Lee, Jonggi Choi, Young-Suk Lim, Baek-Yeol Ryoo, Min-Hee Ryu, & Sook Ryun Park. (2020). Regorafenib Versus Nivolumab After Sorafenib Failure: Real‐World Data in Patients With Hepatocellular Carcinoma. Hepatology Communications, 4, 1073–1086. https://doi.org/10.1002/hep4.1523

Chicago

So Jung Lee, Ju Hyun Shim, Young-Hwa Chung, Young-Sang Lee, Won Mook Choi, Kang Mo Kim, Danbi Lee, et al. 2020. “Regorafenib Versus Nivolumab After Sorafenib Failure: Real‐World Data in Patients With Hepatocellular Carcinoma.” Hepatology Communications 4 (June): 1073–86. doi:10.1002/hep4.1523.